Search Criteria: Research Area is "Research Tools: Tet Expression Systems"
| Stock Number |
Strain Name Phenotype |
Standard Supply |
| 005670 | B6.Cg-Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J | Repository- Live |
| Homozygous mutant mice are viable, fertile, normal in size and do not display any behavioral abnormalities. When these gene targeted mice are bred to transgenic strains expressing Cre recombinase, functional rtTA and EGFP activity is observed in the double mutant offspring in the tissues that express cre. These double mutant mice may be bred to transgenic strains carrying genes of interest under the regulation of tetracycline responsive elements (TRE; tetO) to generate triple mutant mice in which the tissue specificity of the cre-transgenic line and doxycycline inducibility of the rtTA /TRE- (tet-O) controlled transgenes can be combined to regulate expression of the target gene. In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described.
..... | ||
| 007004 | B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ | Repository- Live |
| Transgenic mice expressing the tetracycline-controlled transactivator protein (tTA) under regulatory control of the forebrain-specific calcium-calmodulin-dependent kinase II (Camk2a) promoter are viable and fertile. When hemizygotes are mated to a second strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene can be blocked by administration of the tetracycline analog, doxycycline (dox). These mice are a "Tet-Off" tool that allow the inducible expression of genes in forebrain neurons, and may be useful in studying brain disorders such as Alzheimer's disease (when used in conjunction with Stock No. 005706, Stock No. 007049, Stock No. 007051, Stock No. 007052), Parkinson's
..... For more information please see the full phenotype on the strain data sheet | ||
| 005964 | B6.Cg-Tg(GFAP-tTA)110Pop/J | Repository- Live |
| Mice hemizygous for the transgene are viable fertile, normal in size and do not display any gross physical or behavioral abnormalities. These mice express a tetracycline-controlled transactivator protein (tTA) driven by the human glial fibrillary acidic protein (GFAP) promoter. When these mice are mated to a second transgenic strain that carries a target gene under the regulation of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in astrocytes in the bitransgenic offspring can be induced by withdrawal of the tetracycline analog, doxycycline. Doxycycline may be administered in the animals' water supply. This strain represents an effective tool for generating bitrangenic animals that may be useful to study inducible gene expression in the astrocytes of the central nervous system. | ||
| 006235 | B6.Cg-Tg(SFTPC-rtTA)5Jaw/J | Repository- Live |
| Mice that are hemizygous for this transgenic insert are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the human SFTPC, surfactant, pulmonary-associated protein C, promoter. In situ hybridization detects rtTA gene product (mRNA) in lung peripheral epithelial cells from adult mice and 15 postconception day aged embryos from doxycycline treated dams. Induction of transgene expression is detected as early as postconception day 12.5 when the pregnant female is treated with doxycycline. When mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (tetO), expression of the target gene may be regulated by the tetracycline analog, doxycycline (dox); in the presence of dox, transcription of the target gene is induced in cells where rtTA is
..... For more information please see the full phenotype on the strain data sheet | ||
| 006232 | B6.Cg-Tg(Scgb1a1-rtTA)1Jaw/J | Repository- Live |
| Mice hemizygous for the CCSP-rtTA transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat Scgb1a1, secretoglobin, family 1A, member 1 (uteroglobin), gene promoter. rtTA activity detected in bronchial and type II epithelial cells of lung tissue from adult transgenic mice and in embryos from pregnant females treated with the tetracycline analog doxycycline (dox). In the latter, rtTA-induced expression of a luciferase reporter under the regulation of a tetracycline-responsive promoter (TRE; tetO) has been detected as early as embryonic day 12.5. When hemizygotes are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a TRE, expression of the target gene in the bitransgenic offspring can be regulated by dox; in the presence of dox, transcription of the target
..... For more information please see the full phenotype on the strain data sheet | ||
| 006361 | B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J | Repository- Live |
| Mice hemizygous for this Osx1-GFP::Cre transgene are viable and fertile.
The transgene carries both tTA under the regulation of the osterix (Sp7) promoter and, just downstream, a tetracycline responsive element (TRE; tetO)-controlled GFP/Cre fusion protein. In the absence of the tetracycline analog doxycycline, EGFP-Cre fusion protein expression is restricted to the osteoblast lineage throughout embryonic and early postnatal development. Fusion protein activity is largely absent from chondrocytes. When these transgenic animals are mated to transgenic strains that carry loxP-flanked (floxed) conditional alleles, Cre-mediated recombination of the floxed allele in the double mutant animals is placed under the regulation of doxycycline (dox) such that dox adminstration prevents fusion protein expression and recombination. The donating investigator suggests that the mice be maintained on dox-treated water to avoid incidental effects of tTA expression. These Osx1-GFP::Cre mut
..... For more information please see the full phenotype on the strain data sheet | ||
| 007051 | B6.Cg-Tg(tetO-APPSwInd)102Dbo/J | Repository- Live |
| Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the control of a tissue-specific promoter, APP695swe/ind expression in the appropriate tissues of the bitransgenic offspring can be regulated with the tetracycline analog doxycycline (dox). These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies. For example, when bred to a strain expressing tTA in brain tissues (see Stock No. For more information please see the full phenotype on the strain data sheet | ||
| 007052 | B6.Cg-Tg(tetO-APPSwInd)107Dbo/J | Repository- Live |
| Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, APP695swe/ind expression in the target tissue of the bitransgenic offspring can be regulated with the tetracycline analog doxycycline (dox) in the resulting double mutant offspring.
These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies. For example, when bred to a strain expressing tTA in brain tissues (see Stock No.
..... | ||
| 007049 | B6.Cg-Tg(tetO-APPSwInd)885Dbo/J | Repository- Live |
| Hemizygotes for this tetO-APPswe/ind transgene are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP695) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APP695swe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, APP695swe/ind expression can be regulated in the appropriate tissue of the bitransgenic offspring with the tetracycline analog doxycycline (dox). These tetO-APPswe/ind transgenic mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies. For example, when bred to a strain expressing tTA in brain tissues (see Stock No. For more information please see the full phenotype on the strain data sheet | ||
| 005738 | B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J | Repository- Live |
| Mice homozygous for the transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express Enhanced Green Fluorescent Protein (EGFP) and a truncated dominant-negative mouse transforming growth factor, beta receptor II (Tgfbr2) under the control of a bidirectional tetracycline transactivator responsive promoter (TRE; tetO). No fluorescence is observed in the tissues of this mutant. Primary cultures derived from ear biopsies exhibit green fluorescence when transfected with a tetracycline transactivator (tTA; "Tet-off") vector. When these transgenic mice are bred with other transgenic mice expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), tissue-specific EGFP and dominant-negative Tgfbr2 transgene expression can be regulated with the tetracycline analog, doxycycline. This mutant mouse strain may be useful in studies of TGF-beta signali
..... For more information please see the full phenotype on the strain data sheet | ||
| 006911 | B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J | Repository- Live |
| Mice heterozygous for both targeted mutations (R26-rtTA and Cola1a::tetO-Oct4) are viable and fertile. These "Oct-4/rtTA" mice express rtTA-M2, an optimized form of reverse tetracycline-controlled transactivator (rtTA) protein, in multiple tissues. In the absence of the tetracycline analog doxycycline (dox), Oct4 (Pou5f1) expression from the Col1a1 locus is not detected. Following dox administration, high Oct4 expression is induced in liver, bone marrow, stomach, intestine, and skin, with lower levels in the heart, lungs, kidney, spleen, and thymus; no expression was detected in the brain and testes. Dox-inducd activation of Oct4 results in dysplasia in epithelial tissues. These mutant mice may be useful for studies of tumorigenesis and pluripotent cells. | ||
| 002709 | B6;C3-Tg(TettTALuc)1Dgs/J | Repository- Live |
| Transgenic mice were produced by co-microinjection of modified tetracycline-controlled transactivator (tTA) and luciferase genes placed under the control of tetracycline-responsive promoter elements (TREs). Expression of tTA in transgenic mice is both inducible and autoregulatory; expression of the transgenes are suppressed in the presence of tetracycline and highly expressed in its absence. Induced transgene expression levels are higher than those achieved in strains utilizing a constitutive tTA system. Luciferase expression (in the absence of tetracycline) has been demonstrated in all organs examined - spleen, thymus, lung, liver, kidney, heart, cerebrum, cerebellum, lymph nodes, testes. High activity is found in thymus and lung; low expression is found in liver and kidney. Induction ranges from 2-fold in testes to 150-fold in thymus. The founder line of this strain is #17, as reported in the primary reference. Homozygous mice are viable and fertile. | ||
| 003010 | B6;CBA-Tg(Camk2a-tTA)1Mmay/J | Repository- Live |
| Transgenic mice expressing the tetracycline-controlled transactivator protein (tTA) under regulatory control of the forebrain-specific calcium-calmodulin-dependent kinase II (Camk2a) promoter are viable, fertile, and display no overt phenotypic defects. Transgene expression can be blocked by the administration of the tetracycline analog doxycycline (dox) to the mice. Mating these transgenic mice to a second transgenic strain carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE; tetO) allows dox-inducible expression of the target gene specifically in forebrain neurons, and may be useful in studying brain disorders such as Alzheimer's disease (when used in conjunction with Stock No. 005706, Stock No. 007049, Stock No. 007051, Stock No. 00
..... For more information please see the full phenotype on the strain data sheet | ||
| 007678 | B6;SJL-Tg(KRT14-rtTA)208Jek/J | Repository- Live |
| Homozygous females and hemizygous males carrying this X-linked K14-rtTA transgene (K14-rtTetA(X) or rtTAX) are viable and fertile. These mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the human keratin 14 promoter. As the transgene is located on the X chromosome, random inactivation of the X chromosome may result in mosaic rtTA expression patterns in female mice. When mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE or tetO), expression of the target gene in the basal cells of the squamous epithelia and in the outer root sheath of the hair follicles is induced with administration of the tetracycline analog, doxycycline (dox). These K14-rtTA mice provide a Tet-On tool that allows the inducible expression of genes in skin cells. | ||
| 006004 | B6C3-Tg(tetO-APPSwInd)885Dbo/J | Repository- Live |
| Hemizygous mice are viable and fertile. These transgenic mice express a chimeric mouse/human amyloid precursor protein (APP) bearing the Swedish (KM570/571NL) and Indiana (V617F) mutations associated with Alzheimer's disease (APPswe/ind) under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoters , APPswe/ind transgene expression can be regulated in the appropriate tissue of the bitransgenic offspring with the tetracycline analog, doxycycline. When bred to a strain expressing rtTA or tTA in brain tissues (see Stock No. 003010, for example), this mutant mouse strain may be useful in studies of Alzheimer's Disease. | ||
| 006245 | C.Cg-Tg(SFTPC-rtTA)5Jaw/J | Repository- Live |
| Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the human SFTPC, surfactant, pulmonary-associated protein C, promoter. rtTA activity is detected in lung peripheral epithelial cells from adult mice and in embryos from pregnant females treated with the tetracycline analog, doxycycline (dox). In the latter, rtTA-induced expression of a luciferase reporter under the regulation of a tetracycline-responsive promoter (TRE; tetO) has been detected as early as embryonic day 10.5. When hemizygotes are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a TRE, expression of the target gene in the bitransgenic offspring may be regulated by dox; in the presence of dox, transcription of the target gene is induced in cells where rtTA is expressed. This
..... For more information please see the full phenotype on the strain data sheet | ||
| 006242 | C.Cg-Tg(Scgb1a1-rtTA)1Jaw/J | Repository- Live |
| Mice hemizygous for the CCSP-rtTA transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat Scgb1a1, secretoglobin, family 1A, member 1 (uteroglobin), gene promoter. In situ hybridization detects rtTA gene product (mRNA) in bronchial and type II epithelial cells of lung tissue from adult transgenic mice treated with doxycycline for 7 days. Induction of transgene expression is detected as early as postconception day 14 when the pregnant female is treated with doxycycline. When mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (tetO), expression of the target gene may be regulated by the tetracycline analog, doxycycline (dox); in the presence of dox, transcription of the target gene is induced in cells where rtTA is
..... For more information please see the full phenotype on the strain data sheet | ||
| 006244 | C.Cg-Tg(tetO-cre)1Jaw/J | Repository- Live |
| Hemizygous transgenic mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express Cre recombinase under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the control of tissue-specific promoters, Cre recombinase expression and Cre-mediated recombination in the appropriate tissues of the bitransgenic offspring can be regulated with the tetracycline analog, doxycycline. This strain represents an effective tool for generating inducible tissue specific-targeted mutants to study cell lineage during development.
In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele wa
..... | ||
| 006618 | C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J | Repository- Live |
| Hemizygotes are viable and fertile. These transgenic mice express a mitochondrial-specific EYFP fusion protein under the control of a tetracycline-responsive promoter element (TRE;tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoter, tissue-specific expression of EYFP in mitochondria of the bitransgenic offspring can be regulated with the tetracycline analog, doxycycline. When bred to a strain expressing rtTA or tTA in forebrain neurons (see Stock No. 003010 for example), this mutant mouse strain may be useful in studies of neuronal mitochondrial dysfunction. | ||
| 008099 | FVB-Tg(KRT14-rtTA)F42Efu/J | Repository- Live |
| Mice that are hemizygous or homozygous for this transgenic insert are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the human keratin 14 (KRT14) gene promoter (active in embryonic and postnatal basal cells of the skin). When mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (tetO), expression of the target gene may be regulated by the tetracycline analog, doxycycline (dox); in the presence of dox, transcription of the target gene is induced in cells where rtTA is expressed. This strain provides a Tet-On tool that allows the inducible expression of genes in cells expressing KRT14 for hair and skin research. | ||
| 006439 | FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J | Repository- Live |
| Hemizygous mice are viable and fertile. These transgenic mice express the human KRASG12C mutation under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoters, transgene expression in the appropriate tissues of the bitransgenic offspring can be regulated with the tetracycline analog, doxycycline.
When crossed with mice containing a lung-specific tTA protein (e.g. Stock Nos. 006222, 006232, 006242 or 006225), treatment with doxycycline results in the formation of benign hyperplastic lesions starting
..... | ||
| 006875 | FVB/N-Tg(Tagln-rtTA)E1Jwst/J | Repository- Live |
| Transgenic SM22-rtTA mice are viable and fertile. These mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the murine SM22-alpha (SM22a or transgelin) promoter. When hemizygotes are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring is inducible in smooth muscle cells with administration of the tetracycline analog, doxycycline. These SM22-rtTA mice provide a "Tet-On" tool that allows the inducible expression of genes in smooth muscle cells. | ||
| 006202 | FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J | Repository- Live |
| Hemizygotes are viable, fertile, normal in size, and do not display any behavioral abnormalities. Transgene expression is directed by the tetracycline-responsive element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoters , BCR-ABL1 fusion protein expression can be regulated in the appropriate tissue of the bitransgenic offspring with the tetracycline analog, doxycycline. These mice originally were designed to be bred with transgenic mice harboring a Tal1-tTA transgene (see Stock No. 006209), creating double transgenic offspring as a model for studies of the Philadelphia chromosome and inducible chronic myeloid leukemia. When bred to a strain expressing tTA in the epithelial cells of secretory organs and skin (see Stock No.
..... | ||
| 006999 | STOCK Dbttm1Geh Tg(tTALap)5Bjd Tg(tetO-DBT)A1Geh/J | Repository- Live |
| Mice homozygous for the Dbt (E2) targeted mutation and carrying both the LAP-tTA and TRE-E2 transgenes are viable and fertile. The E2-targeted mutation leads to absence of branched-chain keto acid dehydrogenase (BCKDH) activity and E2 protein in liver tissue, but this absence is rescued by the two transgenes: liver-directed expression of the modified human BCKDH E2 subunit from the complimentary "Tet-off" transgenes abrogates the severity of Maple Syrup Urine Disease (MSUD) phenotype observed in E2-deficient single mutant mice. Triple mutant mice are a model for intermediate MSUD (iMSUD); BCKDH activity is only 5-6% of that found in wildtype mice. This low level of BCKDH activity is sufficient to allow survival, but insufficient to normalize circulating branched chain amino acids levels. Because these mice have near normal amounts of E2 protein, but only 5-6% of normal BCKDH enzyme activity, it is probable that the c-myc tag at the carboxy-terminus of the human E2 transge
..... For more information please see the full phenotype on the strain data sheet | ||
| 005572 | STOCK Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J | Repository- Live |
| Homozygous mutant mice are viable, fertile, normal in size and do not display any behavioral abnormalities. When these gene targeted mice are bred to transgenic strains expressing Cre recombinase, functional rtTA and EGFP activity is observed in the double mutant offspring in the tissues that express cre. These double mutant mice may be bred to transgenic strains carrying genes of interest under the regulation of tetracycline responsive elements (TRE; tetO) to generate triple mutant mice in which the tissue specificity of the Cre-transgenic line and the doxycycline inducibility of the rtTA /TRE-(tet-O) controlled transgenes can be combined to regulate expression of the target gene. Of note, mutant mice are also available on a C57BL/6J genetic background (see Stock No. 005670). | ||
| 003273 | STOCK Tg(rtTAhCMV)4Bjd/J | Repository- Live |
| Homozygous transgenic mice are viable, fertile, and display no overt phenotype. These mice carry the gene encoding the reverse tetracyline-controlled transactivator protein (rtTA) under the control of a human cytomegalovirus early promoter (PhCMV). When these mice are mated to a strain carrying a luciferase reporter gene coupled to a tetracycline-responsive promoter element (TRE; tetO), luciferase expression in the bitransgenic offspring is induced up to 105-fold by treatment with doxycycline (dox) in organs and tissues where PhCMVis known to be active, (i.e. muscle, kidney, thymus and pancreas). Little to no luciferase expression is induced in tissues where PhCMV is not active (i.e. lung, brain, liver and lymphocytes). These mice may be mated to strains containing a gene of interest coupled to a TRE to study the target gene expression effects under tissue-specific, dox-inducible regulation. Dox may be administered in the animals? water suppl
..... For more information please see the full phenotype on the strain data sheet | ||
| 003271 | STOCK Tg(tTAhCMV)3Bjd/J | Repository- Live |
| These mice were imported to The Jackson Laboratory in 1998. In 2005-2006, we confirmed that these mice express little or no tetracycline-controlled transactivator protein (tTA), even in the absence of doxycycline (dox). A similar conclusion was reported in a recent publication (Frugier et al. 2005. Genesis 42:1-5). The phenotype described below is base on the description of the mice in the original publication (Kistner et al, Proc Natl Acad Sci USA 1996 93:10933-8): STOCK Tg(tTAhCMV)3Bjd/J mice are viable, fertile, and display no overt phenotype. These mice express a tetracycline-controlled transactivator protein (tTA) driven by the human early cytomegalovirus promoter (PhCMV. When transgenic mice are mated to a strain carrying a luciferase reporter gene coupled to a tetracycline-responsive promoter element (TRE; tetO), luciferase was expressed in multiple organs and tissues where PhCMV was known to be active (e.g. muscle, kidney, thymus, heart, pancreas) in the
..... | ||
| 005104 | STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J | Repository- Live |
| These transgenic mice express the human histone 1, H2bj, protein (HIST1H2BJ) and Green Fluorescent Protein (GFP) fusion protein, HIST1H2BJ/GFP, under the control of a tetracycline-responsive promoter element (TRE; tetO). Transgenic expression occurs in widespread fashion. When hemizygotes are bred with another transgenic mouse expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) to create bitransgenic animals, tissue-specific HIST1H2BJ/GFP transgene expression can be regulated with the tetracycline analog, doxycycline. Pulse-chase administration of doxycycline results in retention of signal in rarely dividing, or infrequently cycling, label-retaining cells (LRCs). Potential constitutive transgene expression should be examined in tissues of interest. | ||
| 006224 | STOCK Tg(tetO-cre)1Jaw/J | Repository- Live |
| Hemizygous transgenic mice are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express Cre recombinase under the control of a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the control of tissue-specific promoters, Cre recombinase expression and Cre-mediated recombination in the appropriate tissues of the bitransgenic offspring, can be regulated with the tetracycline analog, doxycycline. This strain represents an effective tool for generating inducible, tissue-specific-targeted mutants to study cell lineage during development. Importation of this model was supported by the Boomer Esiason Foundation. | ||
| 003767 | B6.Cg-Tg(Eno2tTA)5021Nes/J | Repository-Cryopreserved |
| These transgenic mice express the tetracycline-controlled activator protein (tTA) under the control of a rat neuron-specific enolase (Eno2) promoter. Although the Eno2 promoter has been shown to direct high levels of expression in brain tissue in general, this strain selectively expresses tTA at high levels in the striatum and cerebellum. When B6.Cg-Tg(Eno2tTA)5021Nes/J transgenic mice are mated to a second transgenic strain carrying a gene of interest under the regulation of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring may be induced in the tTA-expressing tissues by the withdrawal of the tetracycline analog, doxycycline (dox). For example, when these transgenic mice are bred with Stock No. 003762, a transgenic strain that expresses a Fosb variant under the direction of a TRE, the resulting bitransgenic offspring can be induced to express h
..... For more information please see the full phenotype on the strain data sheet | ||
| 003763 | B6.Cg-Tg(Eno2tTA)5030Nes/J | Repository-Cryopreserved |
| These transgenic mice express the tetracycline-controlled activator protein (tTA) under the control of a rat neuron-specific enolase (Eno2) promoter. Although the Eno2 promoter has been shown to direct high levels of expression in brain tissue in general, this strain selectively expresses tTA at high levels in the striatum and to a lesser extent in the cerebral cortex and hippocampus. When these transgenic mice are mated to a second transgenic strain carrying a gene of interest under the regulation of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring may be induced in the tTA-expressing tissues by the withdrawl of the tetracycline analog, doxycycline (dox). For example, when these transgenic mice are bred with Stock No. 003762, a transgenic strain that expresses a Fosb variant under the direction of a TRE, the resulting bitransgenic offspring ca
..... For more information please see the full phenotype on the strain data sheet | ||
| 002618 | B6.Cg-Tg(MMTVtTA)1Mam/J | Repository-Cryopreserved |
| The MMTV-LTR was used to target expression of tetracycline-controlled transactivator protein (tTA) to the epithelial cells of secretory organs and skin in transgenic mice. When Tg(MMTVtTA)1Mam transgenic mice were mated to a second transgenic strains carrying either lacZ or luciferase reporter genes coupled to tetracycline-responsive promoter elements (TRE; tetO), nearly uniform expression of the reporter was found in seminal vesicle, salivary gland, and Leydig cells of the double transgenic offspring. More heterogeneous reporter gene expression patterns were observed in mammary epithelial cells and basal cells of the epidermis. Lower reporter gene expression levels also were observed in a broad range of tissues. Transcriptional activation mediated by tTA was up to several hundred-fold and was abrogated after the administration of tetracycline. MMTV-tTA transgenic mice may be useful in experiments examining the roles of biological factors at defined developmental stages in the epitheli
..... For more information please see the full phenotype on the strain data sheet | ||
| 003563 | B6.Cg-Tg(tTALap)5Bjd/J | Repository-Cryopreserved |
| Hemizygous mice are viable and fertile. These transgenic mice carry the gene encoding the tetracycline-controlled transactivator protein (tTA) driven by the liver-enriched activator protein (PLAP, C/EBP, Cebpb) promoter, and express tTA, specifically, in liver. When these transgenic mice are mated to a strain carrying the luciferase gene coupled to a tetracycline-responsive promoter element (TRE; tetO), the luciferase reporter is expressed in a liver-specific fashion; treatment with doxycycline (dox) prevented transcription of the luciferase reporter in the liver. C57BL/6J-Tg(tTALap)5Uh mice may be mated to transgenic strains containing a gene of interest coupled to a TRE to study the effects of liver specific expression of the target gene in a dox-inducible fashion. Dox concentration may be administered in the animals' water supply. It should be noted that the chromosomal integration site of a TRE-couple transgene may affect the tissue-specific expression of the t
..... For more information please see the full phenotype on the strain data sheet | ||
| 003762 | B6.Cg-Tg(tetFosb)4468Nes/J | Repository-Cryopreserved |
| Mice homozygous for the Fosb transgene are viable and fertile. These mice express a truncated variant of the Fosb transcription factor. The expressed variant is a highly stable isoform found to be induced in the brain (nucleus accumbens) with repeated exposure to commonly abused drugs, such as amphetamine, morphine, nicotine, and phencyclidine. Transcription is directed by a tetracycline-responsive promoter element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing tetracycline-controlled transactivator protein (tTA or rtTA) to create a bitransgenic animal, Fosb expression can be regulated with the tetracycline analog, doxycycline. This transgenic strain can be crossed with strains 003763 or 003767 to produce bitransgenic mice that can be induced to express high levels of the Fosb variant in brain tissue by withdrawing
..... For more information please see the full phenotype on the strain data sheet | ||
| 007618 | B6.Cg-Tg(tetO-Arntl)1Jt/J | Repository-Cryopreserved |
| Hemizygous mice carrying this mutation are viable, fertile, and display no apparent defects or abnormalities. These transgenic mice express a hemaglutinin-tagged copy of the Arntl (Bmal1) gene under the control of a tetracycline-responsive promoter element (TRE or tetO). When bred with another transgenic mouse expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) to create a bitransgenic animal, transgene expression can be regulated with the tetracycline analog, doxycycline. This strain may be useful in studies dilineating the mechanism of mammalian circadian rhythms. | ||
| 002621 | B6;SJL-Tg(tetop-lacZ)2Mam/J | Repository-Cryopreserved |
| B6;SJL-Tg(tetoplacZ)2Mam transgenic mice serve as reporter/tester mice for transgenic mice expressing the tetracycline-controlled transactivator proteins tTA or rtTA. This strain carries a beta-galactosidase (lacZ) reporter gene under the control of a tetracycline-responsive promoter element (TRE; tetO), consisting of the human cytomegalovirus early promoter fused to tet operator sequences. When these mice are mated with transgenic mice expressing tTA or rtTA, lacZ transcription may be induced by the administration (or withdrawl, if tTA is used) of tetracycline, or its analog, doxycyline. Beta-galactosidase activity is not observed in the absence of tTA or rtTA transgene. | ||
| 005706 | C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J | Repository-Cryopreserved |
| Hemizygous transgenic mice are viable, fertile, normal in size and do not display any behavioral abnormalities. Mice homozygous for this transgene may not be viable. When these transgenic mice are bred with mice expressing the tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, expression of the CDK5R1/GFP fusion protein in the appropriate tissue of the bitransgenic offspring can be regulated by doxycycline administration. These mice may be useful in studies of Alzheimer's disease and other neurodegenerative tauopathies, amyotrophic lateral sclerosis (ALS), Niemann Pick Type C (NPC) disease, and Parkinson's disease.
Note: this transgenic strain was designed to breed with Tg(Camk2a-tTA) transgenic mice, (Stock No. 003010), a transgenic strain that expresses tTA in forebrain neurons. The resulting bitransgenic offspring exhibit the hallmark phenotype of Alzheimer's disease;
..... | ||
| 004127 | FVB-Tg(Nes-rtTA)306Rvs/J | Repository-Cryopreserved |
| Mice that are hemizygous for this transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat nestin intron II enhancer/promoter. According to the donating investigator, expression occurs in the neuroepithelium of the developing nervous system (embryonic days 10-17), in some neuron subsets of the adult mouse (e.g. cerebellum, hippocampal dentate gyrus, subventricular zone, spinal cord) and in adult testes. The rtTA gene is cotranscribed with the lacZ reporter gene Bgeo, which allows verification of the site of rtTA expression. When Tg(Nes-rtTA) hemizygous mice are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene may be regulated by the tetracycline analog, doxycycli
..... For more information please see the full phenotype on the strain data sheet | ||
| 005625 | FVB-Tg(Pcp2-tTA)3Horr/J | Repository-Cryopreserved |
| Mice that are homozygous for the transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. Cerebellar Purkinje cell-specific tTA expression has been confirmed using PCR. Constitutive expression of tTA in Purkinje cells makes this strain suitable for creating bitransgenic mice that can, by withdrawing tetracycline (or its derivative doxycycline), inducibly express a gene of interest in Purkinje cells when the gene of interest is under the direction of a tetracycline-responsive element (TRE; tetO). | ||
| 003170 | FVB.Cg-Tg(Myh6-tTA)6Smbf/J | Repository-Cryopreserved |
| This strain expresses the tetracycline-controlled transactivator protein (tTA) under the regulatory control of the rat alpha myosin heavy chain promoter, which directs expression of tTA, specifically, in cardiac myocytes. When these Myh6-tTA (also called 2.9alphatTA or MHCAtTA) transgenic mice are mated to a second transgenic strain carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE), conditional expression of the target gene in cardiac myocytes may be controlled by the administration of tetracycline or doxycycline. | ||
| 006225 | FVB.Cg-Tg(SFTPC-rtTA)5Jaw/J | Repository-Cryopreserved |
| Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. The donating investigator reports that homozygous transgenic mice are not viable. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the human SFTPC, surfactant, pulmonary-associated protein C, promoter. rtTA activity is detected in lung peripheral epithelial cells from adult mice and in embryos from pregnant females treated with the tetracycline analog doxycycline (dox). In the latter, rtTA-induced expression of a luciferase reporter under the regulation of a tetracycline-responsive promoter (TRE; tetO) has been detected as early as embryonic day 10.5. When hemizygotes are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a TRE, expression of the target gene in the bitransgenic offspring can be regulated by dox; in the presence of dox, tra
..... For more information please see the full phenotype on the strain data sheet | ||
| 006222 | FVB.Cg-Tg(Scgb1a1-rtTA)1Jaw/J | Repository-Cryopreserved |
| Mice hemizygous for the CCSP-rtTA transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat Scgb1a1, secretoglobin, family 1A, member 1 (uteroglobin), gene promoter. rtTA activity is detected in bronchial and type II epithelial cells of lung tissue from adult transgenic mice and in embryos from pregnant females treated with the tetracycline analog doxycycline (dox). In the latter, rtTA-induced expression of a luciferase reporter under the regulation of a tetracycline-responsive promoter (TRE; tetO) has been detected as early as embryonic day 12.5. When hemizygotes are mated to a second transgenic strain carrying a gene of interest under the regulatory control of a TRE, expression of the target gene in the bitransgenic offspring can be regulated by dox; in the presence of dox, transcription of the targ
..... For more information please see the full phenotype on the strain data sheet | ||
| 006209 | FVB.Cg-Tg(Tal1-tTA)19Dgt/J | Repository-Cryopreserved |
| Hemizygotes are viable, fertile, normal in size, and do not display any behavioral abnormalities. Hemizygotes express tetracycline-controlled transactivator protein (tTA) in bone marrow hematopoietic stem cells (HSC) and in common myeloid progenitors (CMP)). tTA activity also is detected in lung. Little to no tTA activity is detected in thymus, lymph node, intestine or spleen. When bred to other transgenic mice carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring can be induced by withdrawal of tetracycline or doxycycline. This strain represents an effective tool for generating bitrangenic animals to study inducible gene expression in blood stem and progenitor cells.
These mice were originally designed to be bred with transgenic mice harboring a TRE-BCR-ABL1 transgene (Stock No. 006202), creating bitransgenic offspring as a mo
..... | ||
| 005942 | FVB/N-Tg(Pf4-tTA/VP16)42Kra/J | Repository-Cryopreserved |
| Transgenic mice are viable, fertile, normal in size, and do not display any behavioral abnormalities. Transgenic tetracycline-controlled transactivator protein (tTA) expression is limited to megakaryocytes by the rat chemokine (C-X-C motif) ligand 4 (Cxcl4; formerly called platelet factor four (Pf4)) promoter. When bred to mice carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene is induced specifically in megakaryocytes. Administration of tetracycline/doxycycline sequesters the transgenic protein, and prevents expression of the TRE-regulated target gene.
This mouse originally was designed to be bred with Tg(tetO-Aurkb,lacZ)41Kra (see Stock No. 005941); a transgenic mouse with a bidirectional tetO promoter controlling a mitotic regulator gene (aurora kinase B) and a beta-galactosidase reporter. Megakaryocytes and platelet cells from th
..... | ||
| 005941 | FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J | Repository-Cryopreserved |
| Hemizygous and homozygous transgenic mice are viable, fertile, normal in size, and do not display any behavioral abnormalities. Expression of the bicistronic transgene is directed by a tetracycline-responsive regulatory element (TRE; tetO). When transgenic mice are bred with another transgenic strain expressing the tetracycline-controlled transactivator protein (tTA) under the regulation of a tissue-specific promoter, both aurora kinase B (Aurkb) and lacZ cistrons are inducibly expressed in the appropriate tissue in the bitransgenic offspring. This mouse was originally designed to be bred with Tg(Pf4-tTA)42Kra transgenic mice, which express tTA from a megakaryocyte-specific promoter. Megakaryocytes and platelet cells derived from the bitransgenic offspring show inducible and reversible beta-galactosidase expression. Further, megakaryocytes inducibly express Aurkb mRNA (but not protein) with a modest effect on megakaryocyte ploidy and no effect on platelet quant
..... | ||
| 004375 | FVB/N-Tg(tetO-Kras2)12Hev/J | Repository-Cryopreserved |
| Mice that are homozygous for the transgene are viable and fertile. These transgenic mice express activated rat Kras (Kras4bG12D) under the regulation of a tetracycline-responsive promoter element (TRE; tetO). When these mice are mated to strains containing transgenes encoding either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator), activated Kras expression in the bitransgenic animals can be induced by administration or withdrawl, respectively, of the tetracycline analog, doxycycline. This strain represents an effective tool for generating tissue specific mutants that would be useful models for studying oncogene activation in human carcinogenesis. | ||
| 003315 | FVB/N-Tg(tetORo1-lacZ)3Conk/J | Repository-Cryopreserved |
| Transgenic mice express both Ro1 (Receptor Activated Solely by a Synthetic Ligand (RASSL), opioid, #1) and lacZ under the regulation of tetracycline responsive elements (TRE; tetO)(see Strain Development for more information). When Ro1 is expressed in the heart (by crossing it with strain FVB.Cg-Tg(Myh6-tTA)6Smbf/J - Stock No. 003170), administration of the drug spiradoline produces a dramatic decrease in heart rate. Since Ro1 and lacZ are co-integrated and under tetracycline/doxycycline control, X-gal staining can be used to identify cells in which the tet-inducible system is working. Ro1 activates Gi-signaling in response to spiradoline, and can be used to study the effect of Gi-signaling in many tissues. In the heart, Ro1-mediated activation of Gi-signaling slows heart rate, but in other tissues it is predicted to control diverse physiological events, such as cell proliferation, se
..... For more information please see the full phenotype on the strain data sheet | ||
| 004602 | NOD.Cg-Tg(Ins2-rtTA)2Doi/DoiJ | Repository-Cryopreserved |
| Tg(Ins2-rtTA)2Doi encodes the reverse tetracycline regulatable transactivator (rtTA) regulated by the rat insulin promoter (Ins2, commonly designated RIP), and is expressed in the pancreatic beta cells. Mice hemizygous for this transgenic insert are viable, fertile, normal in size, display normal NOD diabetes onset, but do not display any other gross physical or behavioral abnormalities. When transgenic are mated to a second transgenic strain carrying a target gene regulated by the tetO responsive elements, expression of the target gene is turned on by the tetracycline analog, doxycycline (dox). Dox can be administered orally in the food or water. This strain provides a Tet-On tool that permits the inducible expression of genes in the pancreatic beta cells during various stages of diabetes development (As reported by donating investigator, data unpublished). | ||
| 004937 | NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ | Repository-Cryopreserved |
| Tg(Ins2-tTA)1Doi encodes the tetracycline regulatable transactivator (tTA) regulated by the rat insulin promoter (Ins2, commonly designated RIP), and is expressed in the pancreatic beta cells. Mice hemizygous for this transgenic insert are viable, fertile, normal in size, display normal NOD diabetes onset, but do not display any other gross physical or behavioral abnormalities. When transgenic mice are mated to a second transgenic strain carrying the target gene regulated by the tetO responsive elements, expression of the target gene is turned off by the tetracycline analog, doxycycline (dox). Dox can be administered orally in the food or water. This strain provides a Tet-Off tool that permits the inducible expression of genes in the pancreatic beta cells during various stages of diabetes development. | ||
| 005076 | NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ | Repository-Cryopreserved |
| Mice hemizygous for this transgenic insert are viable, fertile, normal in size. Diabetes incidence and onset is similar to that observed in NOD inbred mice, but otherwise, the mice do not display any gross physical or behavioral abnormalities. These transgenic mutant mice may be mated to strains carrying either rtTA (reverse tetracycline trans-activator protein) or tTA (the tetracycline trans-activator) transgenes regulated by tissue specific promoters. In the bi-transgenic offspring of such crosses, tissue-specific expression of the EGFP/FADD fusion protein can be either induced (in rtTA transgenic mice) or suppressed (in tTA transgenice mice) by administration of the tetracycline analog, doxycycline (dox). Dox may be administered in the animals? water supply. Double transgenic mice generated by intercrossing Tg(tetO-EGFP/FADD)1Doi transgenic mice with NOD.Cg-Tg(Ins2-rtTA)2Doi/DoiJ (Stock No. 004602) transgenic mice express
..... | ||
| 005734 | NOD/Lt-Tg(Ins2-rtTA)1Ach/AchJ | Repository-Cryopreserved |
| Tg(Ins2-rtTA)2Ach encodes the reverse tetracycline regulatable transactivator (rtTA) regulated by the rat insulin promoter (Ins2, commonly designated RIP), and is expressed in the pancreatic beta cells. Hemizygous transgenic mice are viable, fertile, normal in size, display normal NOD diabetes onset, but do not display any other gross physical or behavioral abnormalities. When NOD/Lt-Tg(Ins2-rtTA)2Ach/AchJ mice are mated to a second transgenic strain carrying a target gene regulated by the tetO responsive elements, expression of the target gene is turned on by the tetracycline analog, doxycycline (dox). Dox can be administered orally in the food or water. This strain provides a Tet-On tool that permits the inducible expression of genes in the pancreatic beta cells during various stages of diabetes development (As reported by donating investigator, data unpublished). This transgenic strain is likely to have characteristics similar to Stock No. For more information please see the full phenotype on the strain data sheet | ||
| 005701 | STOCK Pdx1tm1Macd/J | Repository-Cryopreserved |
| Mice homozygous for the targeted mutation fail to develop a pancreas. Heterozygous mice have normal pancreas development but partially impaired glucose tolerance in adulthood. The substitution of the targeted gene with tTAoff inactivates the endogenous allele and places tTAoff expression under the control of the endogenous transcriptional regulatory sequences. tTA expression from the modified locus is identical to that of the normal allele; tTA mRNA is detectable in the pancreas but not in other visceral organs or salivary glands. This mutant may be useful in studies of pancreatic endocrine/exocrine function and diabetes. Heterozygotes also can be bred with transgenic mice that express a target gene under the regulation of a tetracycline-responsive element (TRE; tetO) for pancreas-specific applications.
This mutant was originally designed to be mated with mutant mice with a TRE-controlled transgene coding for the endogenous Pdx1 (Ipf1) gene alon
..... | ||
| 003275 | STOCK Tg(tetL)1Bjd/J | Repository-Cryopreserved |
| STOCK Tg(tetL)1Bjd/J transgenic mice are viable, fertile, and do not display an overt phenotype. These transgenic mice carry the luciferase gene coupled to a tetracycline-responsive promoter element (TRE). When mated to a strain expressing the tetracycline-controlled activator proteins tTA or rtTA coupled to a tissue-specific promoter, luciferase will be expressed in the appropriate tissue in a tetracycline-inducible fashion. | ||
| 003274 | STOCK Tg(tetNZL)2Bjd/J | Repository-Cryopreserved |
| In this strain both the lacZ gene with a nuclear localization signal (NZ) and the luciferase gene (L) are driven by a bidirectional, tetracycline-responsive promoter element (TRE). When mated to a strain expressing the tetracycline-controlled activator proteins tTA or rtTA coupled to tissue-specific promoters, lacZ and luciferase will be expressed in the appropriate tissue in a tetracycline-inducible fashion. According to the donating investigator, the expression of the two reporter genes is biased toward higher levels of lacZ than of luciferase, which, although low, is still measurable. | ||
| 005699 | STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J | Repository-Cryopreserved |
| Mice hemizygous for the transgene are viable, fertile, normal in size, and do not display any behavioral abnormalities. At the Jackson Laboratory, no homozygous mice were produced from mating hemizygotes together, suggesting that homozygous transgenic animals die in utero. Expression of the bicistronic transgene is under the regulation of a tetracycline promoter element (TRE; tetO). By themselves, these transgenic mice do not express EGFP, but when these mice are mated with a second transgenic strain expressing tetracycline-transactivator (tTA) protein under the control of a tissue-specific promoter, Ipf1 and EGFP are highly expressed in the appropriate tissue of bitransgenic offspring.
This mouse was originally designed to be mated to an apancreatic targeted mutant with tTAoff in place of the endogenous Ipf1 gene (see Stock No. 005701). The combined mutations allow normal pancreatic dev
..... | ||
| 005728 | STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J | Repository-Cryopreserved |
| Hemizygous transgenic mice are viable, fertile, normal in size, and do not display any behavioral abnormalities. Expression of the bicistronic transgene is under the regulation of a tetracycline-responsive promoter element (TRE; tetO). When transgenic mice are bred to a second transgenic strain expressing tetracycline-transactivator (tTA) protein under the control of a tissue-specific promoter, the bitransgenic offspring express Ipf1 and lacZ in the appropriate target tissue. Further, Ipf1 and lacZ expression in bitransgenic mice can be suppressed by administration of the tetracycline analog, doxycycline. All cells expressing Ipf1 coexpress the reporter, and mRNA levels of the transgenic and endogenous Ipf1 fluctuate in concert during development. This mouse was designed originally to be mated to an pancreatic targeted mutant with tTAoff in place of the Ipf1 gene (see Stock No. For more information please see the full phenotype on the strain data sheet | ||
(56 stocks) Back to Top
How to Register Interest
Please indicate your interest in purchasing any of the strains listed below when they become available for distribution by checking the box next to the strain(s) of interest and then selecting the "Continue" button which leads to an Interest Form.View a Data sheet for New Strains Under Development
Select the strain name to link to the strain data sheet.
New Strains Under DevelopmentThe Jackson Laboratory serves as a worldwide distributor and national repository for common and rare strains of inbred mice and mice carrying spontaneous mutations or induced mutations (i.e., transgenic, targeted/"knockout", or chemically induced mutations). At any one time, we have over 100 strains at various stages of development and colony expansion. Strains "Under Development" fall into two categories depending on the anticipated demand from the scientific community.
- Receive periodic updates on the status of the colony UNDER DEVELOPMENT
- Obtain advance notification of strain availability and opportunity to order prior to the strain being published as available
- Provide input affecting speed and quantity of availability
It is VERY IMPORTANT that you register interest in strains Under Development. The anticipated demand for a strain enables us to determine effectively the distribution plan for each strain Under Development. Registering interest also provides benefits to you (including advance notification of pending availability). Whether a strain is made available from a live colony OR from our cryopreservation repository, you may want to consider the option of Dedicated Supply. To learn more about Dedicated Supply, go to Services.
- Strains that will be made available from a live distribution colony at The Jackson Laboratory.
These strains are designated as: "Under Development for Distribution Colony"- Strains that will be made available through the Cryopreservation Repository.
These strains are designated as: "Under Development for Cryopreservation Repository"
Send questions to our Technical Support team using the Express Technical Support Form.
(2.15)